English 
Japanese 
March 13, 2026
PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement
PRISM BioLab and Receptor.AI today announced that they have entered into a drug discovery collaboration agreement...
Read More
January 22, 2026
Phase 1 clinical research results of E7386, Jointly Created by PRISMBioLab and Eisai, Published in ESMO OPEN
PRISM BioLab announces that a paper reporting the results of a domestic Phase I clinical trial...
Read More
January 20, 2026
Notice of Tokyo Office Relocation
We would like to inform you that PRISM BioLab will relocate our Tokyo office to the...
Read More
December 18, 2025
PRISM BioLab and Talus Bioscience Announce Joint Research Agreement
PRISM BioLab and Talus Bioscience, Inc. are pleased to announce that we have entered into a...
Read More
November 28, 2025
PRISM BioLab Announces Patent Grant for Novel Bicyclic PepMetics® Compounds
PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on...
Read More
November 18, 2025
Financial Results for the Fiscal Year Ended September 2025 (Japanese GAAP) (Non-Consolidated)
Financial Results for the Fiscal Year Ended September 2025 (Japanese GAAP) (Non-Consolidated)
Read More
November 14, 2025
PRISM BioLab Announces Achievement of Initial Milestone and Receipt of Upfront Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
PRISM BioLab is pleased to announce that we have achieved the initial milestone in our drug...
Read More
November 6, 2025
PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical
PRISM BioLab is pleased to announce that a Phase I clinical study on drug-drug interactions of...
Read More
October 21, 2025
Eisai to Present Clinical Trial and Biomarker Exploration Results of E7386, Co-Created with PRISM BioLab, at the ESMO Annual Congress
TOKYO, Japan, October 17, 2025: -- PRISM BioLab announces that Eisai Co., Ltd. will present clinical...
Read More
October 3, 2025
PRISM BioLab Announces Patent Grant for Novel Bicyclic PepMetics® Compounds
PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on...
Read More